XML 24 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

9. Stock-Based Compensation

In May 2021, the Company’s board of directors (the "Board") adopted, and its stockholders approved, the 2021 Equity Incentive Plan (the “2021 Plan”), which became effective in connection with the IPO. The 2021 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code ("IRC"), to the Company’s employees and any of its parent or subsidiary corporations’ employees, and for the grant of non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, and performance awards to the Company’s employees, directors and consultants and any of its parent or subsidiary corporations’ employees and consultants. A total of 10,459,000 shares of the Companys Class A common stock have been reserved for issuance under the 2021 Plan in addition to (i) an annual increase of 4% of the outstanding shares of the Company's common stock, with Class A and Class B common stock taken together, on the first day of each fiscal year, subject to the Compensation Committee of the Board exercising discretion to increase or decrease such amount (the “Evergreen Addition”), and (ii) upon the expiration, forfeiture, cancellation, or reacquisition of any shares of Class B common stock underlying outstanding stock awards granted under the 2012 Equity Incentive Plan, an equal number of shares of Class A common stock, such number of shares not to exceed 7,563,990. On January 1, 2024, pursuant to the Evergreen Addition, approximately 5.0 million shares of Class A common stock were added to the 2021 Plan issuance reserve. At March 31, 2024, there were approximately 21.7 million remaining shares available for the Company to grant under the 2021 Plan.

Stock Options

A summary of the Company’s option activity during the three months ended March 31, 2024 was as follows (in thousands, except share and per share amounts):

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

Weighted-

 

 

Average

 

 

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Aggregate

 

 

Options

 

 

Exercise Price

 

 

Contractual

 

 

Intrinsic

 

 

Outstanding

 

 

per Share

 

 

Life (years)

 

 

Value

 

Outstanding at December 31, 2023

 

3,849,350

 

 

$

7.87

 

 

 

5.06

 

 

$

38,505

 

Options exercised

 

(67,746

)

 

 

1.44

 

 

 

 

 

 

 

Options forfeited

 

(1,333

)

 

 

8.66

 

 

 

 

 

 

 

Outstanding at March 31, 2024

 

3,780,271

 

 

$

7.98

 

 

 

4.85

 

 

$

55,817

 

Exercisable at March 31, 2024

 

3,732,980

 

 

$

7.97

 

 

 

4.83

 

 

$

55,161

 

No options were granted or expired during the three months ended March 31, 2024. Aggregate intrinsic value represents the difference between the exercise price of the options and the fair value of the Company’s common stock.

Restricted Stock Units (“RSUs”)

A summary of the Company’s RSU activity during the three months ended March 31, 2024 was as follows:

 

 

 

 

Weighted-

 

 

 

 

 

Average

 

 

Number of

 

 

Grant Date

 

 

RSUs Outstanding

 

 

Fair Value

 

Awarded and unvested at December 31, 2023

 

1,946,006

 

 

$

12.74

 

Awards granted

 

995,548

 

 

 

19.20

 

Awards vested

 

(235,619

)

 

 

11.42

 

Awards forfeited

 

(25,580

)

 

 

9.89

 

Awarded and unvested at March 31, 2024

 

2,680,355

 

 

$

15.28

 

The fair value of RSU grants is determined based upon the market closing price of the Company’s Class A common stock on the date of grant. RSUs vest over the requisite service period, which generally ranges between four years and five years from the date of grant for employees and one to three years for directors, subject to continued employment for employees and provision of services for nonemployees.

Stock-based compensation expense included in the condensed consolidated statements of operations was as follows:

 

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

 

 

(in thousands)

 

Cost of revenue

 

$

51

 

 

$

45

 

Research and development

 

 

608

 

 

 

546

 

Sales and marketing

 

 

1,310

 

 

 

716

 

General and administrative

 

 

964

 

 

 

852

 

Total stock-based compensation

 

$

2,933

 

 

$

2,159

 

At March 31, 2024, there was $0.1 million of total unrecognized compensation cost related to unvested stock options granted under the 2012 Equity Incentive Plan, which is expected to be recognized over a remaining weighted-average period of 1.4 years.

At March 31, 2024, there was $38.5 million of total unrecognized compensation cost related to unvested RSUs granted under the 2021 Plan, which is expected to be recognized over a remaining weighted-average period of 3.8 years.